Dr Reddy’s

Galena Biopharma, Dr. Reddy’s partner for NeuVax in India

Wednesday, January 15, 2014

Galena Biopharma, a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, and Dr. Reddy’s Laboratories, an integrated global pharmaceutical company, have announced a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India.

[Read More]

Dr. Reddy’s profits skyrocket

Monday, May 16, 2011

India-based Dr. Reddy’s Laboratories says that net income for the fourth quarter doubled to $75 million due to strong generic drug sales in the U.S., as reported in Pharma Times.

[Read More]

In India, A Pairing Born Of Necessity

Monday, October 9, 2006

India’s clinical research market entered a new era in January 2005 with the signing of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. TRIPS requires the country to honor all product patents issued after 1995.

[Read More]